Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 1:45 AM
Ignite Modification Date: 2025-12-26 @ 12:03 AM
NCT ID: NCT00556894
Description: None
Frequency Threshold: 5
Time Frame: None
Study: NCT00556894
Study Brief: Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Placebo Matching Placebo q12 for 12 weeks None None 3 84 1 84 View
CF101 0.1mg CF101 0.1mg q12 for 12 weeks None None 3 82 2 82 View
CF101 1mg CF101 1mg q12 for 12 weeks None None 2 87 5 87 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Alanine aminotransferase and Aspartate aminotransferase increased None Investigations None View
Eyelid oedema None Eye disorders None View
Nausea and Diarrhoea None Gastrointestinal disorders None View
Pancytopenia None Blood and lymphatic system disorders None View
Microcytic anemia None Blood and lymphatic system disorders None View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Nausea None Gastrointestinal disorders None View